Restricted delivery of talazoparib across the blood–brain barrier limits the sensitizing effects of PARP inhibition on temozolomide therapy in glioblastoma

Sani Kizilbash, Shiv K. Gupta, Kenneth Chang, Ryo Kawashima, Karen E. Parrish, Brett L. Carlson, Katrina K. Bakken, Ann C. Mladek, Mark A. Schroeder, Paul A. Decker, Gaspar J. Kitange, Yuqiao Shen, Ying Feng, Andrew A. Protter, William F. Elmquist, Jann N Sarkaria

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Poly ADP-ribose polymerase (PARP) inhibitors, including talazoparib, potentiate temozolomide efficacy in multiple tumor types; however, talazoparib-mediated sensitization has not been evaluated in orthotopic glioblastoma (GBM) models. This study evaluates talazoparib ± temozolomide in clinically relevant GBM models. Talazoparib at 1-3 nmol/L sensitized T98G, U251, and GBM12 cells to temozolomide, and enhanced DNA damage signaling and G2-M arrest in vitroIn vivo cyclical therapy with talazoparib (0.15 mg/kg twice daily) combined with low-dose temozolomide (5 mg/kg daily) was well tolerated. This talazoparib/temozolomide regimen prolonged tumor stasis more than temozolomide alone in heterotopic GBM12 xenografts [median time to endpoint: 76 days versus 50 days temozolomide (P = 0.005), 11 days placebo (P < 0.001)]. However, talazoparib/temozolomide did not accentuate survival beyond that of temozolomide alone in corresponding orthotopic xenografts [median survival 37 vs. 30 days with temozolomide (P = 0.93), 14 days with placebo, P < 0.001]. Average brain and plasma talazoparib concentrations at 2 hours after a single dose (0.15 mg/kg) were 0.49 ± 0.07 ng/g and 25.5±4.1 ng/mL, respectively. The brain/plasma distribution of talazoparib in Bcrp-/- versus wild-type (WT) mice did not differ, whereas the brain/plasma ratio in Mdr1a/b-/- mice was higher than WT mice (0.23 vs. 0.02, P < 0.001). Consistent with the in vivo brain distribution, overexpression of MDR1 decreased talazoparib accumulation in MDCKII cells. These results indicate that talazoparib has significant MDR1 efflux liability that may restrict delivery across the blood-brain barrier, and this may explain the loss of talazoparib-mediated temozolomide sensitization in orthotopic versus heterotopic GBM xenografts.

Original languageEnglish (US)
Pages (from-to)2735-2746
Number of pages12
JournalMolecular Cancer Therapeutics
Volume16
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

temozolomide
Poly(ADP-ribose) Polymerases
Glioblastoma
Therapeutics
Heterografts
Brain
talazoparib
Placebos

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Restricted delivery of talazoparib across the blood–brain barrier limits the sensitizing effects of PARP inhibition on temozolomide therapy in glioblastoma. / Kizilbash, Sani; Gupta, Shiv K.; Chang, Kenneth; Kawashima, Ryo; Parrish, Karen E.; Carlson, Brett L.; Bakken, Katrina K.; Mladek, Ann C.; Schroeder, Mark A.; Decker, Paul A.; Kitange, Gaspar J.; Shen, Yuqiao; Feng, Ying; Protter, Andrew A.; Elmquist, William F.; Sarkaria, Jann N.

In: Molecular Cancer Therapeutics, Vol. 16, No. 12, 01.12.2017, p. 2735-2746.

Research output: Contribution to journalArticle

Kizilbash, S, Gupta, SK, Chang, K, Kawashima, R, Parrish, KE, Carlson, BL, Bakken, KK, Mladek, AC, Schroeder, MA, Decker, PA, Kitange, GJ, Shen, Y, Feng, Y, Protter, AA, Elmquist, WF & Sarkaria, JN 2017, 'Restricted delivery of talazoparib across the blood–brain barrier limits the sensitizing effects of PARP inhibition on temozolomide therapy in glioblastoma', Molecular Cancer Therapeutics, vol. 16, no. 12, pp. 2735-2746. https://doi.org/10.1158/1535-7163.MCT-17-0365
Kizilbash, Sani ; Gupta, Shiv K. ; Chang, Kenneth ; Kawashima, Ryo ; Parrish, Karen E. ; Carlson, Brett L. ; Bakken, Katrina K. ; Mladek, Ann C. ; Schroeder, Mark A. ; Decker, Paul A. ; Kitange, Gaspar J. ; Shen, Yuqiao ; Feng, Ying ; Protter, Andrew A. ; Elmquist, William F. ; Sarkaria, Jann N. / Restricted delivery of talazoparib across the blood–brain barrier limits the sensitizing effects of PARP inhibition on temozolomide therapy in glioblastoma. In: Molecular Cancer Therapeutics. 2017 ; Vol. 16, No. 12. pp. 2735-2746.
@article{7731fe6c942844b8810b3a0ca3254a9c,
title = "Restricted delivery of talazoparib across the blood–brain barrier limits the sensitizing effects of PARP inhibition on temozolomide therapy in glioblastoma",
abstract = "Poly ADP-ribose polymerase (PARP) inhibitors, including talazoparib, potentiate temozolomide efficacy in multiple tumor types; however, talazoparib-mediated sensitization has not been evaluated in orthotopic glioblastoma (GBM) models. This study evaluates talazoparib ± temozolomide in clinically relevant GBM models. Talazoparib at 1-3 nmol/L sensitized T98G, U251, and GBM12 cells to temozolomide, and enhanced DNA damage signaling and G2-M arrest in vitroIn vivo cyclical therapy with talazoparib (0.15 mg/kg twice daily) combined with low-dose temozolomide (5 mg/kg daily) was well tolerated. This talazoparib/temozolomide regimen prolonged tumor stasis more than temozolomide alone in heterotopic GBM12 xenografts [median time to endpoint: 76 days versus 50 days temozolomide (P = 0.005), 11 days placebo (P < 0.001)]. However, talazoparib/temozolomide did not accentuate survival beyond that of temozolomide alone in corresponding orthotopic xenografts [median survival 37 vs. 30 days with temozolomide (P = 0.93), 14 days with placebo, P < 0.001]. Average brain and plasma talazoparib concentrations at 2 hours after a single dose (0.15 mg/kg) were 0.49 ± 0.07 ng/g and 25.5±4.1 ng/mL, respectively. The brain/plasma distribution of talazoparib in Bcrp-/- versus wild-type (WT) mice did not differ, whereas the brain/plasma ratio in Mdr1a/b-/- mice was higher than WT mice (0.23 vs. 0.02, P < 0.001). Consistent with the in vivo brain distribution, overexpression of MDR1 decreased talazoparib accumulation in MDCKII cells. These results indicate that talazoparib has significant MDR1 efflux liability that may restrict delivery across the blood-brain barrier, and this may explain the loss of talazoparib-mediated temozolomide sensitization in orthotopic versus heterotopic GBM xenografts.",
author = "Sani Kizilbash and Gupta, {Shiv K.} and Kenneth Chang and Ryo Kawashima and Parrish, {Karen E.} and Carlson, {Brett L.} and Bakken, {Katrina K.} and Mladek, {Ann C.} and Schroeder, {Mark A.} and Decker, {Paul A.} and Kitange, {Gaspar J.} and Yuqiao Shen and Ying Feng and Protter, {Andrew A.} and Elmquist, {William F.} and Sarkaria, {Jann N}",
year = "2017",
month = "12",
day = "1",
doi = "10.1158/1535-7163.MCT-17-0365",
language = "English (US)",
volume = "16",
pages = "2735--2746",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Restricted delivery of talazoparib across the blood–brain barrier limits the sensitizing effects of PARP inhibition on temozolomide therapy in glioblastoma

AU - Kizilbash, Sani

AU - Gupta, Shiv K.

AU - Chang, Kenneth

AU - Kawashima, Ryo

AU - Parrish, Karen E.

AU - Carlson, Brett L.

AU - Bakken, Katrina K.

AU - Mladek, Ann C.

AU - Schroeder, Mark A.

AU - Decker, Paul A.

AU - Kitange, Gaspar J.

AU - Shen, Yuqiao

AU - Feng, Ying

AU - Protter, Andrew A.

AU - Elmquist, William F.

AU - Sarkaria, Jann N

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Poly ADP-ribose polymerase (PARP) inhibitors, including talazoparib, potentiate temozolomide efficacy in multiple tumor types; however, talazoparib-mediated sensitization has not been evaluated in orthotopic glioblastoma (GBM) models. This study evaluates talazoparib ± temozolomide in clinically relevant GBM models. Talazoparib at 1-3 nmol/L sensitized T98G, U251, and GBM12 cells to temozolomide, and enhanced DNA damage signaling and G2-M arrest in vitroIn vivo cyclical therapy with talazoparib (0.15 mg/kg twice daily) combined with low-dose temozolomide (5 mg/kg daily) was well tolerated. This talazoparib/temozolomide regimen prolonged tumor stasis more than temozolomide alone in heterotopic GBM12 xenografts [median time to endpoint: 76 days versus 50 days temozolomide (P = 0.005), 11 days placebo (P < 0.001)]. However, talazoparib/temozolomide did not accentuate survival beyond that of temozolomide alone in corresponding orthotopic xenografts [median survival 37 vs. 30 days with temozolomide (P = 0.93), 14 days with placebo, P < 0.001]. Average brain and plasma talazoparib concentrations at 2 hours after a single dose (0.15 mg/kg) were 0.49 ± 0.07 ng/g and 25.5±4.1 ng/mL, respectively. The brain/plasma distribution of talazoparib in Bcrp-/- versus wild-type (WT) mice did not differ, whereas the brain/plasma ratio in Mdr1a/b-/- mice was higher than WT mice (0.23 vs. 0.02, P < 0.001). Consistent with the in vivo brain distribution, overexpression of MDR1 decreased talazoparib accumulation in MDCKII cells. These results indicate that talazoparib has significant MDR1 efflux liability that may restrict delivery across the blood-brain barrier, and this may explain the loss of talazoparib-mediated temozolomide sensitization in orthotopic versus heterotopic GBM xenografts.

AB - Poly ADP-ribose polymerase (PARP) inhibitors, including talazoparib, potentiate temozolomide efficacy in multiple tumor types; however, talazoparib-mediated sensitization has not been evaluated in orthotopic glioblastoma (GBM) models. This study evaluates talazoparib ± temozolomide in clinically relevant GBM models. Talazoparib at 1-3 nmol/L sensitized T98G, U251, and GBM12 cells to temozolomide, and enhanced DNA damage signaling and G2-M arrest in vitroIn vivo cyclical therapy with talazoparib (0.15 mg/kg twice daily) combined with low-dose temozolomide (5 mg/kg daily) was well tolerated. This talazoparib/temozolomide regimen prolonged tumor stasis more than temozolomide alone in heterotopic GBM12 xenografts [median time to endpoint: 76 days versus 50 days temozolomide (P = 0.005), 11 days placebo (P < 0.001)]. However, talazoparib/temozolomide did not accentuate survival beyond that of temozolomide alone in corresponding orthotopic xenografts [median survival 37 vs. 30 days with temozolomide (P = 0.93), 14 days with placebo, P < 0.001]. Average brain and plasma talazoparib concentrations at 2 hours after a single dose (0.15 mg/kg) were 0.49 ± 0.07 ng/g and 25.5±4.1 ng/mL, respectively. The brain/plasma distribution of talazoparib in Bcrp-/- versus wild-type (WT) mice did not differ, whereas the brain/plasma ratio in Mdr1a/b-/- mice was higher than WT mice (0.23 vs. 0.02, P < 0.001). Consistent with the in vivo brain distribution, overexpression of MDR1 decreased talazoparib accumulation in MDCKII cells. These results indicate that talazoparib has significant MDR1 efflux liability that may restrict delivery across the blood-brain barrier, and this may explain the loss of talazoparib-mediated temozolomide sensitization in orthotopic versus heterotopic GBM xenografts.

UR - http://www.scopus.com/inward/record.url?scp=85038563739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038563739&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-17-0365

DO - 10.1158/1535-7163.MCT-17-0365

M3 - Article

C2 - 28947502

AN - SCOPUS:85038563739

VL - 16

SP - 2735

EP - 2746

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 12

ER -